UK-based pharmaceutical giant AstraZeneca Inc., (AZ, NASDAQ: AZN) has announced that its Phase III CAPItello-281 study has successfully met its primary endpoint of radiographic progression-free survival (rPFS). The study evaluated the efficacy of Truqap (capivasertib) in combination with abiraterone and androgen deprivation therapy (ADT) for patients with PTEN-deficient de novo metastatic hormone-sensitive prostate cancer (mHSPC). The results indicate a significant and clinically meaningful improvement in rPFS.
Truqap Combo Therapy: Early Positive Results for Prostate Cancer Patients
The Truqap combination therapy has shown promising early results, with an overall survival (OS) data analysis revealing immature results at the time of the study. However, there is an early trend suggesting an improvement in OS, which is a positive sign for the treatment’s potential impact on patient outcomes.
Truqap: A First-in-Class AKT Inhibitor with Global Approvals
Truqap is a first-in-class, potent, adenosine triphosphate (ATP)-competitive inhibitor targeting all three AKT isoforms (AKT1/2/3). It was approved by the US FDA in November 2023 for use in combination with fulvestrant for HR+, HER2- locally advanced or metastatic recurrent or refractory cancers with specific biomarker changes. Building on this, Truqap received marketing approval in Japan in March of this year, expanding its global reach and potential to improve treatment options for cancer patients.-Fineline Info & Tech
